Walk into a modern musculoskeletal clinic and you might see two very different types of physicians sharing the same waiting room: a regenerative medicine doctor preparing to perform a bone marrow concentrate injection, and an orthopedic surgeon scrubbing for a knee replacement down the hall. To a patient with chronic knee, hip, or back pain, both doctors seem to promise the same thing: getting back to a life that does not revolve around pain. Yet their tools, training, and philosophies differ in important ways.
As someone who has spent years referring patients back and forth between orthopedic surgeons and regenerative physicians, I can tell you that choosing the right type of doctor often matters more than any single procedure. The lines are getting blurrier, though, as more orthopedic surgeons adopt biologic therapies and more regenerative doctors are trained originally in orthopedics, sports medicine, or physical medicine and rehabilitation.
Understanding the differences, and where the overlap makes sense, helps you make smarter choices about surgery, injections, cost, and realistic expectations.
What is a regenerative medicine doctor?
In a simple sense, a regenerative medicine doctor is a physician who uses the body’s own cells, tissues, and signaling molecules to help repair or improve damaged structures, rather than removing or replacing them surgically. Many patients ask, very directly, “What is a regenerative medicine doctor?” The answer is less about a board certification and more about a practice focus.
Most regenerative physicians are trained first in a core specialty such as:
- physical medicine and rehabilitation (PM&R) sports medicine anesthesiology and pain medicine family medicine or internal medicine with musculoskeletal focus orthopedic surgery itself
After that, they complete additional training in image-guided injections, cellular therapies, and related biologic treatments. Some university centers have formal regenerative medicine fellowships, but a lot of real-world expertise comes from procedural volume, outcome tracking, and a willingness to say “no” when an injection is unlikely to help.
In practice, a regenerative medicine doctor may:
- aspirate bone marrow or harvest fat tissue to prepare cell-rich concentrates process platelet-rich plasma (PRP) from your blood inject these preparations under ultrasound or fluoroscopic guidance into joints, tendons, ligaments, or the spine combine these procedures with meticulous rehab, bracing, and activity modification
They generally try to preserve or restore native tissue, rather than replace it with metal, plastic, or donor tissue.
An important nuance: “regenerative medicine” is a broad umbrella that also includes gene therapy, tissue engineering, and organ regeneration in research settings. In an orthopedic clinic, though, you are mostly dealing with orthobiologic injections: PRP, bone marrow concentrate, sometimes fat-derived products.
What is an orthopedic surgeon?
An orthopedic surgeon is a physician who completes medical school, then a 5-year orthopedic surgery residency, often followed by a fellowship in subspecialties such as sports medicine, spine, hand, or joint replacement. Their training is surgical from day one. They are experts at:
- fixing fractures with plates, screws, or rods reconstructing torn ligaments and tendons performing arthroscopic procedures inside joints with cameras and small instruments replacing arthritic joints with prosthetic implants
Many orthopedic surgeons also offer injections such as corticosteroids, viscosupplementation (hyaluronic acid), and sometimes PRP, but the core of their toolbox remains operative.
In terms of income, orthopedics routinely ranks near the top among the highest paid doctor specialties in the United States. Surveys often place average orthopedic compensation in the 500,000 to 650,000 USD per year range, with some subspecialists exceeding that. This matters mainly because it helps explain why surgical infrastructure is well developed, heavily insured, and strongly marketed, while regenerative options often lag in regulatory clarity and insurance coverage.
For context, the lowest paying doctor specialty brackets in the U.S. Typically include primary care fields such as pediatrics, family medicine, and some preventive medicine roles, often in the 220,000 to 270,000 USD range. That gap influences who can spend a career doing primarily cash-based regenerative work versus relying on traditional insurance-based practice.
Key philosophical and practical differences
Orthopedic surgeons and regenerative medicine doctors often see the same problem through different lenses. When you strip away marketing language, some core differences usually show up.
Here is a concise side-by-side view of how they commonly differ in approach:
- Primary toolkit: Orthopedic surgeons focus on structural repair or replacement with hardware and prosthetics. Regenerative doctors focus on biologic repair, using cells, platelets, and growth factors. Training path: Orthopedic surgery involves intensive operative training and hospital-based work. Regenerative practice typically grows out of non-surgical specialties with added procedural and biologic training. Typical setting: Surgeons spend more time in the operating room and hospital. Regenerative physicians spend most of their time in procedure rooms and clinics. Time horizon: Surgeons often intervene later, when damage is advanced and mechanical failure is obvious. Regenerative doctors typically work earlier in the disease course, trying to slow or partially reverse deterioration. Risk profile: Surgery carries higher upfront risk but can offer dramatic structural changes. Well-performed orthobiologic injections usually have lower procedural risk but more modest and variable results.
In practice, these differences are not absolute. A thoughtful orthopedic surgeon may strongly advocate non-operative care and only use surgery as a last resort. Some regenerative medicine doctors are, in fact, orthopedic surgeons who shifted their practice toward biologic approaches.
The best outcomes often appear when both philosophies cooperate: using regenerative injections to delay a joint replacement, or using PRP around a surgically repaired tendon to improve healing.
The biggest problem with regenerative medicine
Patients often ask, “What is the biggest problem with regenerative medicine?” From a clinician’s perspective, the main issue is not that these treatments never work. The problem is how uneven the evidence, regulation, and marketing have been.
Several overlapping challenges show up again and again:
First, the term “stem cell” is abused. Many clinics advertise stem cell therapy when they are injecting amniotic or umbilical cord products that, once processed, contain no living stem cells. True autologous stem-cell-rich procedures, such as bone marrow concentrate, are completely different in biology, regulation, and reasonable expectations.
Second, clinical evidence is patchy. There is solid, growing data for some applications, such as PRP for mild to moderate knee osteoarthritis or certain tendinopathies. There is weaker or highly mixed evidence for advanced bone-on-bone arthritis, multilevel spinal degeneration, or systemic anti-aging claims. Yet the marketing often blurs these lines.
Third, regulation lags behind innovation. In the U.S., the FDA has issued multiple warnings about unproven stem cell clinics, but enforcement is inconsistent. Patients read about a celebrity success story and assume the same treatment is standardized and vetted, when in fact quality can vary dramatically from one clinic to another.
Fourth, the economics amplify hype. Because most regenerative procedures are cash-pay, financial incentives can skew counseling. It is not unusual for someone to walk into my office after being quoted 8,000 to 15,000 USD for a package of injections that has only a slim chance of helping their specific condition.
The Regenerative Medicine Doctor Scottsdale result is a field with real promise, real success stories, and also real disappointment. Misaligned expectations and aggressive marketing are, in my view, the biggest structural problems with regenerative medicine right now.
What does a regenerative medicine doctor actually earn?
“How much do regenerative medicine doctors make?” is a fair question, because it shapes how practices are built and what gets offered.
Unlike orthopedic surgery, regenerative medicine is not a single board-certified specialty with standardized salary surveys. Income varies widely depending on the doctor’s base specialty, geographic region, procedure mix, and how much of their revenue is cash-based.
Some rough patterns from real-world practices in the U.S.:
A physiatrist or sports medicine physician who incorporates PRP and some bone marrow concentrate into an otherwise insurance-based practice might earn in the 300,000 to 450,000 USD range.
A fully cash-pay regenerative practice in a higher-income area, with a heavy focus on expensive orthobiologic injections and concierge-style care, can push into the 500,000 to 700,000 USD or higher range, especially if the physician owns the clinic and related imaging or lab infrastructure.
On the lower end, a primary care physician dabbling in basic PRP without much procedural volume may remain closer to typical primary care income, in the mid 200,000s.
Those ranges are broad, but they underline an important point: financial incentives in regenerative medicine can be strong. Patients should be aware of that when they are being recommended a high-ticket procedure.
Costs, insurance, and the question everyone dreads
For most people, the central issue is, “Will insurance pay for regenerative medicine?” In musculoskeletal care, the answer is usually no, at least in the U.S.
Most commercial insurers and Medicare do not cover:
- platelet-rich plasma (PRP) injections for orthopedic indications bone marrow concentrate or adipose-derived “stem cell” procedures for joints or spine branded orthobiologic products marketed for regeneration, including many that sound high-tech
A few exceptions exist. Occasionally, certain biologic products used in specific surgical or wound applications may be covered. A small number of plans are experimenting with PRP coverage for clearly defined conditions, but this is not yet mainstream.
So what is the average cost of regenerative medicine in orthopedics? Typical U.S. Price ranges, as of recent years:
PRP injections for a single joint often range from 600 to 1,500 USD per session, with some clinics selling packages of two or three sessions.
Bone marrow concentrate procedures tend to cost between 3,500 and 8,000 USD per area treated, depending on the region and whether the spine is involved.
More complex multi-level spine or “whole body” packages can climb past 10,000 USD. At that point, I strongly advise patients to pause and ask for published data, patient-reported outcome rates, and second opinions.
Regarding specific branded treatments, a common question is, “Does insurance cover Kinetix?” Since brand landscapes shift, the safest general statement is this: most insurers do not cover proprietary regenerative or orthobiologic products for joint pain if they are billed as stand-alone “regenerative” treatments. Coding and coverage vary by plan and region, so anyone considering Kinetix or similar products should check with both the clinic and their insurer, and insist on written confirmation of coverage or lack of coverage.
From a practical standpoint, if paying out of pocket would create financial strain, it is usually wiser to lean on insured options such as physical therapy, weight management, activity modification, and, when appropriate, time-tested surgeries.
Who is a good candidate for regenerative medicine?
The patients who do best with biologic treatments often share a few common features. That does not mean others cannot benefit, but it shapes the probability curve.
Here is a simple checklist many of us use when identifying who is a good candidate for regenerative medicine in an orthopedic or sports setting:
- Structural damage is mild to moderate, not completely destroyed or bone-on-bone on imaging. Pain is significant, but the joint or tendon still functions, and the person is active or motivated to be. The patient has already tried good-quality conservative care such as physical therapy, bracing, appropriate medications, and activity changes. The person understands that success rates are not 100 percent, that improvement is the goal rather than a guaranteed cure, and that rehab after the procedure is not optional. Financially, they can afford the treatment without jeopardizing basic needs or taking on high-interest debt.
By contrast, people with severely collapsed joints, major deformities, or gross instability are often better served by surgical solutions. I have seen patients with years of bone-on-bone knee arthritis who spent thousands on repeated “stem cell” or PRP injections that had almost no realistic chance of restoring cartilage. A frank conversation earlier could have saved them both money and time.
Age alone is not an absolute barrier. I have seen successful PRP and bone marrow concentrate outcomes in patients in their 60s and even 70s, provided tissue damage is not too advanced and systemic health is reasonable. On the flip side, a young athlete with advanced osteochondral damage can sometimes be a poor candidate for injections and a better one for cartilage restoration surgery.
What is the success rate of regenerative medicine?
When patients ask, “What is the success rate of regenerative medicine?” I always push for specifics. Success of what, for which condition, with which product, at what dose, and using which definition of success?
Where the data is strongest, such as PRP for mild to moderate knee osteoarthritis, meta-analyses suggest that a majority of patients, often in the 60 to 70 percent range, achieve meaningful pain reduction and functional improvement for 6 to 12 months or longer. Those are averages across carefully selected patients, not guarantees.
Bone marrow concentrate for knee arthritis shows improvement in many small to mid-size studies, but protocols differ so widely that you will see success ranges anywhere from about 50 percent “significant improvement” to 80 percent “some improvement,” often with no clear control group.
For chronic tendinopathies, such as tennis elbow or patellar tendinopathy, PRP also has supportive evidence, with success rates commonly reported in the 60 to 80 percent improvement range in selected populations.
In contrast, for severe, end-stage osteoarthritis or diffuse, multilevel spinal degeneration, success rates drop and become much harder to predict. Here, regenerative treatments may provide partial, temporary relief rather than durable change, and surgery often has stronger data.
When a clinician gives a flat “95 percent success rate,” without defining population and metrics, skepticism is healthy.
Is regenerative medicine painful?
The discomfort associated with these treatments varies. Most patients tolerate them well, but it is not the same as a simple vaccine shot.
Bone marrow aspiration from the pelvis, which is often used to harvest stem-cell-containing marrow for concentration, can be uncomfortable. With good local anesthesia and, in some clinics, light oral or IV sedation, most patients describe it as pressure and brief sharp pain during certain moments. Soreness over the hip can last a few days.
PRP injections into superficial tendons or joints usually produce brief sting from the local anesthetic, followed by pressure. In some areas, such as the plantar fascia or certain ligaments, the procedure can be quite sore for a short period. This is usually manageable with rest and simple analgesics.
Post-procedure, patients often experience a flare of pain for several days as the injected area reacts. This is typically followed by a gradual, week-by-week improvement if the treatment helps. Most protocols restrict high-impact activity for several weeks and encourage targeted rehab.
So when someone asks, “Is regenerative medicine painful?” the honest answer is: there is temporary pain and soreness around the procedure, but for most patients it is manageable, brief, and far less than the pain of major surgery.
The “4 types of regeneration” and what they mean clinically
Another question that surfaces online is, “What are the 4 types of regeneration?” Biologists sometimes classify regeneration into categories like epimorphosis and morphallaxis, which describe how certain animals regrow limbs. In clinical regenerative medicine, doctors often think more practically.
One useful framework divides regenerative approaches into four broad types:
Cell therapies, such as bone marrow concentrate or, in research settings, cultured stem cell lines, where the cells themselves are central.
Tissue engineering, where cells are combined with scaffolds and growth factors to build or repair structures like cartilage or skin.
Biomaterials and scaffolds, where synthetic or biologic materials are implanted to support native tissue repair, sometimes without adding cells.
Gene and molecular therapies, which alter cell behavior by tweaking gene expression or delivering signaling molecules.
In everyday orthopedic practice, most routine regenerative work occurs in the first category: cell-based and platelet-based injections using your own tissues. The other three categories are growing in research and specialized centers, but have not yet become routine for joint and spine care.
Fasting, cell regeneration, and what it does not do
The question “Does fasting for 72 hours regenerate cells?” reflects a growing interest in lifestyle-driven regeneration. Some animal studies and small human trials have suggested that prolonged fasting can trigger changes in hematopoietic stem cells, immune cell profiles, and metabolic pathways. A notable set of studies from the University of Southern California reported that cycles of prolonged fasting in mice could promote stem cell–based regeneration of certain blood and immune cells.
However, translating that into clinical promises is risky. There is no credible evidence that a 72-hour fast will regrow knee cartilage, reverse advanced spinal disc degeneration, or fix a torn tendon. For most orthopedic patients, the most meaningful metabolic “regeneration” still comes from sustained weight loss, improved muscle strength, and better vascular health.
Prolonged fasting can also be dangerous in people with diabetes, eating disorders, certain heart conditions, or on specific medications. Anyone considering it should do so under medical guidance, and with realistic expectations about what it can and cannot regenerate.
Risks and disadvantages of regenerative medicine
Every honest discussion of these treatments should include, “What are the disadvantages of regenerative medicine?”
The biggest disadvantages in the musculoskeletal realm include:
Cost and lack of insurance coverage, which we have already touched on. High out-of-pocket costs can delay or crowd out other effective care.
Variable evidence and quality. Some procedures have solid data; others are still largely experimental. Clinics differ greatly in training, imaging guidance, and outcome tracking.
Risk of infection or bleeding. Although infection rates are low in experienced hands, any needle-based procedure that passes through skin into a joint or spine carries some risk.
Delayed definitive treatment. Patients may spend months trying repeated injections for a joint that really needs a replacement, or a spine that would be better stabilized surgically. During that time, function and quality of life can deteriorate.
Emotional disappointment. When marketing oversells, and biology underdelivers, the sense of betrayal can be worse than the original pain.
Well-practiced regenerative physicians mitigate these disadvantages by being selective, data-driven, and open about the limits. They sometimes recommend surgery, bracing, or traditional pain management when Regenerative Medicine Doctor Scottsdale those are clearly more appropriate.
International options: where did Joe Rogan go, and what country is “best”?
Celebrities often drive interest in stem cell therapy. Joe Rogan has publicly discussed traveling to Panama for stem cell treatment, specifically to receive high-dose intravenous mesenchymal stem cell infusions at a clinic there. This has led many patients to ask, “What country is best for stem cell treatment?”
There is no universally “best” country. Instead, there are countries with stricter regulations and evidence requirements, and others with looser oversight that allow treatments not yet approved at home.
In the U.S., many autologous procedures using your own minimally manipulated cells are permitted, but expanded or culture-grown stem cell therapies are tightly regulated. Some European countries follow similar strict standards.
Countries like Panama, Mexico, and parts of Eastern Europe have clinics offering treatments that go beyond what is allowed in the U.S. Some are operated by serious scientists; others are pure marketing. The quality, dose, and long-term safety data often remain unclear.
For orthopedic issues like knee arthritis, shoulder tendon tears, or spine degeneration, there is currently no convincing evidence that flying abroad for systemic stem cell infusions offers better outcomes than well-performed, image-guided, local procedures done at home for appropriate indications. Medical tourism also introduces risks around follow-up, emergency care, and legal recourse.
If you are considering traveling, insist on peer-reviewed publications, independent outcome data, and clear information about the exact cell product, dose, and safety profile, not just testimonials and celebrity endorsements.
So which doctor should you see?
Orthopedic surgeons and regenerative medicine doctors are not rivals by default. They are different craftsmen with different tools. The right choice depends on three main questions:
What exactly is structurally wrong? Imaging, physical exam, and your symptom pattern help determine whether the problem is primarily mechanical failure that demands reconstruction, or biologic wear and inflammation that might respond to biologic repair.
How advanced is the damage? Early to moderate disease with preserved alignment and stability is where regenerative options have the most rational role. Gross deformity, collapse, or severe instability tips the scale toward surgery.
What are your goals, risk tolerance, and financial resources? If you cannot accept even small procedural uncertainty, a well-studied joint replacement with clear survival curves may feel more reassuring. If you are highly surgery-averse and can afford a trial of regenerative therapy, then a carefully selected injection, done by an experienced physician, can be worth exploring.
In many patients, the journey is staged. They start with conservative care, then consider regenerative injections when standard measures plateau, and eventually, if and when biologic options no longer provide adequate relief, they move to surgery. Throughout that path, having both an orthopedic surgeon and a regenerative-minded physician you trust makes the decisions less overwhelming and more grounded in your actual anatomy, not just the latest buzzword.
Integrated Spine, Pain and Wellness
7425 E Shea Blvd Suite 102, Scottsdale, AZ 85260
4806608823